Clinical Trial

A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-19; most recent amendment 2026-04-20.
Status change: Active, Not Recruiting → Completed 2026-03-23
Status change: Recruiting → Active, Not Recruiting 2026-02-03
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07141511
Lead Sponsor BeOne Medicines
Conditions Healthy Volunteers
Enrollment 24 participants
Start Date 2025-09-24
Primary Completion 2026-02-23 (estimated)
Study Completion 2026-02-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-22